Cabotegravir with rilpivirine for treating HIV-1

2.1 Cabotegravir (Vocabria, Viiv Healthcare) with rilpivirine (Rekambys, Janssen) is indicated 'for the treatment of HIV‑1 infection in adults who are virologically suppressed (HIV‑1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class'.

2.2 The dosage schedules are available in the summary of product characteristics for cabotegravir and the summary of product characteristics for rilpivirine.

2.3 The list price for cabotegravir is £638.57 for a 30‑day pack of oral tablets and £1,197.02 for the bi‑monthly (every 2 months) intramuscular injection vial (excluding VAT). The list price for rilpivirine is £200.27 for a 30‑day pack of oral tablets and £440.47 for the bi‑monthly intramuscular injection vial (excluding VAT). The company has a commercial arrangement (simple discount patient access scheme). This makes cabotegravir with rilpivirine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.